Psychedelic Business Spotlight - May 20

Psychedelic Business Spotlight – May 20

,
This week in psychedelic business news: Another psychedelic merger; an Optimi Health acquisition; and good news for alcohol abuse treatment.

Psychedelic Capitalism Takes a Trip to Davos

,
From May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here's why that matters for the psychedelics industry.
MindMed, atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisShutterstock

Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis

, ,
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.

MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20 Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/ Follow us on Twitter: The Psychedelic Investor: @PSYCBiz Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @psycbiz @psycspotlight ❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon. Stay tuned for more updates! In today's episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results. MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today. Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose. The results were very positive, though perhaps not paradigm shifting — yet. The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety. The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points. Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing. Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.” In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.” Interested in reading the article? Click here: 👇 MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/ #MindMed #Anxiety #MNMD

Psychedelic Business Spotlight – May 13

,
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
MindMed's Phase 2 LSD Trial Treating Anxiety Was a SuccessShutterstock

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success

, ,
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Why Wednesday Will Be Biggest Day for Psychedelic Investors of 2022Shutterstock

Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors

,
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.

Field Trip And Wesana Make Major Moves | FTRP, WESA

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20 Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/ Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/ Why Field Trip Health Is Dividing in Two — and What This Means for Investors https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/ In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies. Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics. Follow us on Twitter: James: @Psy_Invest Maria: @psy_holy The Psychedelic Investor: @PSYCBiz Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @psycbiz @psycspotlight To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/ To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/ Field Trip Press Release: https://www.globenewswire.com/news- release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development Field Trip Health: In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities. Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd. Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation. Wesana: On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics. The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division. Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow. @psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
Shutterstock

Five Telling Takeways from Benzinga Psychedelics Capital Conference

Psychedelic Spotlight's video producer attended the inaugural Benzinga Psychedelic Capital Conference, and here's what he walked away with.

Psychedelic Business Spotlight – May 6

,
This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on anorexia; Completion launches psychedelic VR NFTs.